Skip to main content

Table 2 Summary of interviews with patients/caretakers

From: Feasibility and acceptability of injectable artesunate for the treatment of severe malaria in the Democratic Republic of Congo

Question/parameter Frequency Percentage [95 % CI]
Time to observe effects of injectable artesunate compared to quinine (N = 134)?
 Less time 125 93.3 [87.6, 96.9]
 Same time 8 6 [2.6, 11.4]
 More time 1 0.7 [0.0, 4.1]
Have you noticed any adverse event that you think could be related to artesunate (N = 134)?
 Yes 46 34.3 [26.4, 43.0]
 No 88 65.7 [57.0, 73.7]
If you noticed adverse events, would you say that: (N = 46)
 They are less than those observed with quinine 32 69.6 [54.3, 82.3]
 They are the same than those observed with quinine 7 15.2 [6.3, 28.9]
 They are more than those observed with quinine 1 2.1 [0.0, 11.5]
 Don’t know 6 13.1 [4.9, 26.3]
If you had to make the choice in the future between quinine and artesunate, which one would you choose (N = 121)?
 Quinine 4 3.3 [0.9, 8.2]
 Artesunate 117 96.7 [91.8, 99.1]
What is your level of satisfaction towards injectable artesunate (N = 134)?
 Dissatisfied 6 4.5 [1.7, 9.5]
 Satisfied 66 49.2 [40.5, 58.0]
 Very satisfied 62 46.3 [37.6, 55.1]
Most important reasons for choosing injectable artesunate instead of injectable quinine (N = 117)
 Rapid action 55 47.0 [37.7, 56.5]
 No side effects 38 32.5 [24.1, 41.8]
 Short treatment course 24 20.5 [13.6, 28.9]
 Less side effects 14 12.0 [6.7, 19.3]
 Rapid way of administration 13 11.1 [6.1, 18.3]
 Short hospital stay 7 6.0 [2.4, 11.9]
 More effective 5 4.2 [1.4, 9.7]